We would love to hear your thoughts about our site and services, please take our survey here.
The share option for JMC and another director was 19 p both Lindy and JMC bought in recently at 11p
Only way is up !
No one can afford to wait
I
Think Seth is a good call after all he has a a degree in pharmacology?
All three subjects will present students with a challenging, technical course, that requires a great level of research and dedication. Pharmacologists, toxicologists, and pharmacists are all contributing to the care of patients through medicine, so the level of training is extremely high.
Sorry about my typos etc a reminder of the CFO credentials, from RNS "Commenting on his appointment as Chief Financial Officer, Sath Nirmalananthan said: I am excited to
be joining Scancell at such a pivotal time. With the Phase 2 single arm SCOPE trial progressing and initialtopline data readouts expected this year and Modi-1 next year, the Company is positioned with highly valuablescience and near-term inflection points that should deliver value to our shareholders. I look forward to working
with Lindy and the wider team and am excited by the potential of what can be achieved.” :
Sath Nirmalananthan is an experienced finance professional with over 15 years experience across healthcare
in FTSE and NASDAQ listed companies, investment banking and audit. Before joining Scancell, Sath was
Chief Financial Officer for Europe, Middle-East and Africa at Prenetics, a leading genomics-driven health
sciences company. Prior to that, Sath worked at Reckitt where he was Finance Director for Group Reporting
and subsequently for eCommerce in Reckitt’s Health Division. Sath has also held senior positions at BTG plc,
a specialty pharmaceutical company, including Director of Group Reporting and Director of FP&A of
interventional oncology. Earlier in his career, he was an equity research analyst in the healthcare team at
Nomura and prior to that an auditor at KPMG. Sath earned a BSc in Pharmacology from King’s College,
London, UK and holds an ACA (ICAEW), Chartered Accountant qualification. Sath is also a Non-Executive
member of the audit committee at The Institute of Cancer Research (ICR).
Prof Lindy Durrant, Chief Executive Officer of Scancell, commented: We are excited to have Sath join
us as Chief Financial Officer. His financial acumen and extensive track record of building value in emerging
biopharmaceutical companies will benefit Scancell in our next stage of evolution. I look forward to working with
him closely as we continue to focus the clinical development of our two lead cancer vaccine assets, SCIB1
and Modi-1, whilst continuing to leverage the potential of our proprietary antibody platform through additional
licensing and revenue generating opportunities. We are very grateful for Keith s excellent financial guidance
which has been invaluable to Scancell s success to date and are pleased that he will continue as
Morning , I suspected Scancell would be at the conference for the filling reasons
1. The festive message stating 2023 milestones
2. The Stiffel buy rates
3. the time frame being early 2024 for data
4. JPC statement at the AGM
5. the fund raise to ensure money is there for the pipeline Scancell wish to focus on , can imagine the confidence in the data , sorry no deal we have enough money ,
6, number of patients on the scope trial easier to recruit as clinician s keen
7. LD comments after her keynote speech about what Moderna person said
8. Moderna in new year media overdrive to get as much publicity as possible
9. the Liverpool Head and neck Symposium , and the slides questioning whether personalised vaccines were a way forward ?
10. last year 2022 AGM Lindy said not much media coverage , because when the news hits its Going to be BIG
11, the introduction at the AGM was " leading Global Immunology " or something like that ?
12. Downplayed the connection with Texas Biomed
13. new healthcare funds on board
14. Red mile continued support and share uptake and connection the JP Morgan and also the conference is on their home turf ,
15 prof Lindy Durrant and Scancell have done an outstanding job , quietly beavering away , tight lipped , IP patents in place , Patients in clinic , money in the bank , and a strong healthcare focused management team and a Chairman who is focused and bought shares
finally the finishing paragraph
To close the year, we were pleased to announce a successful oversubscribed and upsized fundraise of £11.9 million and would like to thank our new and existing investors for their support.
Finally, we would also like to thank the whole Scancell team for their continued efforts and hard work during 2023. Now, with a bolstered leadership team, a strong cash position to fund our current strategy and with further key data inflection points from both the SCOPE and ModiFY trial anticipated, 2024 looks to be another exciting year.
good luck to Seth and the entire Scancell team , including the Patients on trial and the Patience its needed to be "invited to the 2024 JP Morgan healthcare event "
RNS Monday morning would be lovely
IHope the latest data is released for the scope trial.modi and Covidity is released next week to coincide , which will be most interesting and indeed Moderna will have a few issues
Companies/news/1037493/scancell-us-investment-bank-resumes-coverage-with-punchy-price-target-1037493.html
Stifel has resumed coverage of biopharmaceutical company Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) with a repeat of its 'buy' recommendation and 30p target price - a significant premium to the current 11p share price.
Agree Bermuda this is a very poor communications. Especially after the recent fundraising. astonished that our CEO would even mention a further large fund particularly after the initial smaller one. Of 11 mil
we shareholders need an answer about this communication?
What was the question asked to give the £30-60 mil fund raise answer ?
Thinking aloud does anyone think they may be looking for a big manufacturing partner moving forward because if the melanoma trial is a successful as we all had to believe and it could get approval pretty quickly in which case there is a big manufacturer already on board to market and distribute what do you think of that?
As 2023 draws to a close, we reflect on another successful year which saw some significant milestones for Scancell.
We were very pleased to announce positive data from the first stage of our Phase 2 SCOPE trial with the cancer vaccine, SCIB1, for advanced melanoma, demonstrating an objective response rate of 85%. The trial moved into its second phase and is on track to read-out in H1 2024. Based upon the first 13 patients, there is a greater than 90% probability that the second phase will also be successful.
We also continued to make good progress with Modi-1, the first vaccine based on our Moditope® platform, completing dose escalation and safety cohorts in the Phase 1/2 ModiFY trial demonstrating early signs of efficacy in several hard-to-treat cancers. We are expecting early clinical data for Modi-1 in 2024.
Scancell’s GlyMab® and AvidiMab® antibody platforms have also demonstrated significant potential for licensing opportunities, with discussions ongoing with several Pharmaceutical and Biotech companies.
Over the course of the year, we have further strengthened the management team and were delighted to appoint Dr @Jean-Michel Cosséry as Non-Executive Chairman of the Board and welcome our new Chief Financial Officer Sath Nirmalananthan and Head of Business Development Mandeep Sehmi to the Scancell family.
To close the year, we were pleased to announce a successful oversubscribed and upsized fundraise of £11.9 million and would like to thank our new and existing investors for their support.
Finally, we would also like to thank the whole Scancell team for their continued efforts and hard work during 2023. Now, with a bolstered leadership team, a strong cash position to fund our current strategy and with further key data inflection points from both the SCOPE and ModiFY trial anticipated, 2024 looks to be another exciting year.
#Immunotherapy #Cancervaccines #cancervax #Immunooncology #HappyNewYear #2024
I am sure this guy will be there
Nachi S.
Managing Director at Redmile Group
Contact
Nachi S. has had extensive work experience in the finance industry. Nachi is currently serving as the Managing Director at Redmile Group since 2021. Prior to this, Nachi worked at J.P. Morgan for over a decade in various leadership roles, including Executive Director of Private Markets, Executive Director of Global Cash Equities, Vice President of Global Cash Equities, and Associate of Global Cash Equities. Before joining J.P. Morgan, Nachi worked as the Vice President of Institutional Equities at Bear, Stearns & Co. Inc. in 2008. Nachi started their career at Bear, Stearns & Co. Inc. in 2005 as an Analyst in Institutional Equities.
Nachi S. attended UC Irvine from 2001 to 2005. No information is available about the degree or field of study pursued during this
https://aum13f.com/fund/redmile-capital-fund-lp
The time and place to update on the modify and scope trial could be the J.P. Morgan 42nd Annual Healthcare Conference will take place 8-11 January 2024 in San Francisco, CA, USA.
where the big pharma will be watching ?
From Markus on the other side his post :
“HARTAJ SINGH: You know, it's interesting, Josh. I would say it's all of the above, and I'll tell you why. One of the things we as analysts look for when we talk about a platform company, you know, quote unquote, like a Moderna, and not every biotech is a platform company, in fact, they are very few and far between, is can the platform help the company get better clinical and regulatory success rates?
Said Markus
this is analysts look at "Why a platform company ? " Moderna is a Platform company few and far between !
Excellent article states exactly why
https://news.crunchbase.com/health-wellness-biotech/biotech-platform-investment/
“Why platforms?
In the high-risk, high-reward world of biotech venture investment, platforms provide a much-needed steady stream of opportunities.
Most drugs on the market are the result of years of research and development, clinical trials and a painstaking federal approval process. On average, it costs $985 million and takes 10 years to get a drug to market. The path involves scrounging up research grants, development costs and pursuing clinical trials.
Biotech platforms offer a new solution: Instead of investing in a single molecule, a single clinical asset, and taking it to market, what if you could invest in a “machine” that makes many of them?
“It’s not one single molecule that we invested in, it’s not even a series of molecules,” Thomson said. “It’s a platform to create new molecules that we invested in.”
Interview with the analyst who upgraded Moderna
https://www.youtube.com/watch?v=Y7V6Sbj7IPE
A little more digging
Interview with the analyst who upgraded Moderna
https://www.youtube.com/watch?v=Y7V6Sbj7IPE
Moderna is a high performance company
Interview from Lindy Durrant , I believe she mentions the melanoma 50% ( unfortunate for the other 50% )
https://youtu.be/vwC-brP5Ceg
The media coverage
https://www.fiercebiotech.com/biotech/scancell-enjoys-stock-bounce-back-dna-cancer-vaccine-data-snapshot
“Patients received SCIB1 via a needle-free device. Of the nine patients who have shown a response with radiological imaging at a 13-week evaluation, the reduction in tumor volume ranged from 31%-94%, the biotech said. The company is aiming to beat the 50% ORR of the Opdivo-Yervoy combo alone.
RELATED
Moderna places even bigger bet on cancer vaccines, strikes $1.7B Immatics biobucks deal
“Previous studies indicated that a response rate of 50% was the best that could be achieved in the real world setting for patients with unresectable metastatic melanoma, as no other combination had improved on the response rates for doublet CPI alone,” Scancell CEO Lindy Durrant said in the release. “Confirmation of this data in a larger cohort could make a significant impact on melanoma patient survival, especially as melanoma is now one of the most common cancers in young women.”
A little about the Analyst Oppenheimer & Co Analyst, Hartaj Singh
https://www.tipranks.com/experts/analysts/hartaj-singh
Rishi Sunak and the blind trust ( holding Moderna shares )
https://www.businesstoday.in/latest/world/story/did-rishi-sunak-benefit-from-covid-vaccine-maker-modernas-stock-rise-heres-what-the-uk-pm-has-to-say-370386-2023-02-15
Moderna have received an abundance and media coverage for their personalised melanoma vaccine ,
I imagine when the figures for the new scope trial are released its going to be interesting
https://finance.yahoo.com/video/oppenheimer-analyst-explains-why-upgraded-215254260.html
TF
First big one of the year watch the video. ? Hopefully Scancell progress with Melanoma vaccine will be mentioned? Imagine Redmile will be attending ?
Https://www.jpmorgan.com/about-us/events-conferences/health-care-conference
Wishing you a year ahead that's as bright and hopeful as a sunrise.
Good article and a reminder , early 2024 there should be some very interesting results ?
so Redmile . Lindy and JPC stocked up on shares .
remember more data more money . The recent fund rise means that they can enter all negotiations in a much stronger position ,? still keen to know who the new health fund investor is and the evaluation of the cell therapy company . Moderna as had a lot of media coverage to the melanoma vaccine . so looking forward to early 2024 for the "exciting trailblazing " results to knock your socks off !
https://www.fiercebiotech.com/biotech/scancell-enjoys-stock-bounce-back-dna-cancer-vaccine-data-snapshot
Wishing each and everyone of you peace joy and happiness
May you have walls for the winds, a roof for the rain and tea beside the fire. Laughter to cheer you, those you love near you, and all your heart might desire. May joy and peace surround you, Contentment latch your door, And happiness be with you now, And bless you evermore
As 2023 draws to a close, we reflect on another successful year which saw some significant milestones for Scancell.
We were very pleased to announce positive data from the first stage of our Phase 2 SCOPE trial with the cancer vaccine, SCIB1, for advanced melanoma, demonstrating an objective response rate of 85%. The trial moved into its second phase and is on track to read-out in H1 2024. Based upon the first 13 patients, there is a greater than 90% probability that the second phase will also be successful.
We also continued to make good progress with Modi-1, the first vaccine based on our Moditope® platform, completing dose escalation and safety cohorts in the Phase 1/2 ModiFY trial demonstrating early signs of efficacy in several hard-to-treat cancers. We are expecting early clinical data for Modi-1 in 2024.
Scancell’s GlyMab® and AvidiMab® antibody platforms have also demonstrated significant potential for licensing opportunities, with discussions ongoing with several Pharmaceutical and Biotech companies.
Over the course of the year, we have further strengthened the management team and were delighted to appoint Dr @Jean-Michel Cosséry as Non-Executive Chairman of the Board and welcome our new Chief Financial Officer Sath Nirmalananthan and Head of Business Development Mandeep Sehmi to the Scancell family.
To close the year, we were pleased to announce a successful oversubscribed and upsized fundraise of [£11.9] million and would like to thank our new and existing investors for their support.
Finally, we would also like to thank the whole Scancell team for their continued efforts and hard work during 2023. Now, with a bolstered leadership team, a strong cash position to fund our current strategy and with further key data inflection points from both the SCOPE and ModiFY trial anticipated, 2024 looks to be another exciting year.
#Immunotherapy #Cancervaccines #cancervax #Immunooncology #HappyNewYear #2024